PDCD1 and malignant colon neoplasm: Thus, the combination of OX40L/PPT with PD-1 immune checkpoint blockade resulted in significant treatment efficiency enhancement in CT26gfp subcutaneous colon cancer model, and led to protective immunity against CT26gfp colon cancer cells.